JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Guardant Health Inc

Cerrado

SectorSalud

69.57 -1.71

Resumen

Variación precio

24h

Actual

Mínimo

68.28

Máximo

70.83

Métricas clave

By Trading Economics

Ingresos

-4.7M

-100M

Ventas

29M

232M

Margen de beneficio

-43.044

Empleados

1,999

EBITDA

22M

-89M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

-1.51% downside

Dividendos

By Dow Jones

Próximas Ganancias

29 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

3.5B

9B

Apertura anterior

71.28

Cierre anterior

69.57

Noticias sobre sentimiento de mercado

By Acuity

21%

79%

38 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Guardant Health Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 oct 2025, 23:50 UTC

Acciones populares

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 oct 2025, 23:25 UTC

Ganancias

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 oct 2025, 23:18 UTC

Ganancias

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 oct 2025, 22:20 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 oct 2025, 22:13 UTC

Ganancias

Wal-Mart de Mexico Net Profit Falls in 3Q

28 oct 2025, 21:38 UTC

Ganancias

Correction to Visa Sales Jump Article

28 oct 2025, 21:17 UTC

Ganancias

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 oct 2025, 21:07 UTC

Ganancias

Visa Sales Jump as Consumers Keep Spending -- Update

28 oct 2025, 21:02 UTC

Ganancias

Mondelez Tempers Outlook as Costs Rise

28 oct 2025, 23:51 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 oct 2025, 23:02 UTC

Ganancias

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 oct 2025, 23:01 UTC

Ganancias

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 oct 2025, 22:46 UTC

Ganancias

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 oct 2025, 22:45 UTC

Ganancias

SK Hynix 3Q Net KRW12.6T >000660.SE

28 oct 2025, 22:44 UTC

Ganancias

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 oct 2025, 22:43 UTC

Ganancias

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 oct 2025, 22:42 UTC

Ganancias

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 oct 2025, 22:40 UTC

Ganancias

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 oct 2025, 22:22 UTC

Ganancias

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 oct 2025, 22:20 UTC

Ganancias

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 oct 2025, 22:02 UTC

Ganancias

Review & Preview: Earnings Extravaganza -- Barrons.com

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

28 oct 2025, 21:42 UTC

Charlas de Mercado
Ganancias

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 oct 2025, 21:20 UTC

Ganancias

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 oct 2025, 21:19 UTC

Ganancias

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 oct 2025, 21:18 UTC

Ganancias

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparación entre iguales

Cambio de precio

Guardant Health Inc Esperado

Precio Objetivo

By TipRanks

-1.51% caída

Estimación a 12 meses

Media 71.06 USD  -1.51%

Máximo 90 USD

Mínimo 60 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Guardant Health Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

21

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

38.86 / 47.41Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

38 / 373 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat